Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Diatrizoic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.78 |
| ▸ | LMNA | P02545 | 4/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diatrizoic Acid SCHEMBL4334352 | 0.95 | SMN1; SMN2 (0.87) | SMN1; SMN2LMNAKDM4E | |
| Diatrizoic Acid SCHEMBL2501947 | 0.89 | SMN1; SMN2 (0.97) | SMN1; SMN2LMNAKDM4E | |
| Diatrizoic Acid SCHEMBL720469 | 0.88 | SMN1; SMN2 (1.00) | SMN1; SMN2LMNAKDM4E | |
| Diatrizoic Acid SCHEMBL1685085 | 0.88 | SMN1; SMN2 (1.00) | SMN1; SMN2LMNAKDM4E | |
| Diatrizoic Acid SCHEMBL107036 | 0.88 | SMN1; SMN2 (1.00) | SMN1; SMN2LMNAKDM4E | |
| Diatrizoic Acid SCHEMBL468613 | 0.86 | SMN1; SMN2 (0.97) | SMN1; SMN2LMNAKDM4E | |
| Diatrizoic Acid SCHEMBL10763445 | 0.84 | LMNA (0.59) | SMN1; SMN2LMNA | |
| Iothalamic Acid SCHEMBL29488709 | 0.80 | SMN1; SMN2 (0.84) | SMN1; SMN2LMNAKDM4E | |
| Iothalamic Acid SCHEMBL180546 | 0.80 | SMN1; SMN2 (0.84) | SMN1; SMN2LMNAKDM4E | |
| Iothalamic Acid SCHEMBL48785 | 0.80 | SMN1; SMN2 (0.84) | SMN1; SMN2LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12582606-B2 | Tablet and method for producing tablet | SUNSHO PHARMACEUTICAL CO., LTD. (JP) | 2026-03-24 | — | — | US | disclosed |
| WO-2024043306-A1 | COMPOSITION FOR FLUORESCENT LABELING, FLUORESCENT PROBE, INJECTION AGENT, SYRINGE FILLING, MEDICAL APPARATUS, MEDICAL FIBER MATERIAL, METHOD FOR PRODUCING COMPOSITION FOR FLUORESCENT LABELING, AND METHOD FOR PRODUCING MEDICAL FIBER MATERIAL | 株式会社ヴィータ | 2024-02-29 | — | — | WO | disclosed |
| US-20230256193-A1 | MEDICAL DEVICE | OLYMPUS MEDICAL SYSTEMS CORP. (JP) | 2023-08-17 | — | — | US | disclosed |
| CN-114929233-A | Phosphodiesterase type V inhibitor compositions, methods of making them, and methods of using them | 美国瑞根特有限公司 | 2022-08-19 | — | — | CN | disclosed |
| US-20220218616-A1 | TABLET AND METHOD FOR PRODUCING TABLET | SUNSHO PHARMACEUTICAL CO., LTD. (JP) | 2022-07-14 | — | — | US | disclosed |
| US-20210205172-A1 | DRUG MANAGEMENT METHOD FOR KIT FORMULATION REQUIRING DOSE ADJUSTMENT | REGIMEN KIT INC (JP) | 2021-07-08 | — | — | US | disclosed |
| EP-3838246-A1 | DRUG MANAGEMENT METHOD FOR KIT FORMULATION REQUIRING DOSE ADJUSTMENT | Regimen Kit, Inc. (JP) | 2021-06-23 | — | — | EP | disclosed |
| US-10716861-B2 | Composition intended to vectorise an anti-cancer agent | GUERBET (FR) | 2020-07-21 | — | — | US | disclosed |
| CN-110753541-A | Pharmaceutical compositions for in vivo delivery, process for preparing substantially water insoluble pharmacologically active agents | ZY治疗公司 | 2020-02-04 | — | — | CN | disclosed |
| US-10292627-B2 | Method and apparatus for noninvasive detection of potential symptomless blood loss | BIOPOTENTIAL OY LTD (FI) | 2019-05-21 | — | — | US | disclosed |
| EP-0639375-A1 | A bile duct deterging composition | Senju Pharmaceutical Co., Ltd. (JP) | 1995-02-22 | — | — | EP | disclosed |
| US-5271923-A | Solid radiographic contrast medium | MANAC INCORPORATED (JP) | 1993-12-21 | — | — | US | disclosed |
| US-5271923-A | Solid radiographic contrast medium | MANAC INCORPORATED (JP) | 1993-12-21 | — | — | US | disclosed |
| EP-0374266-B1 | SOLID X-RAY CONTRAST MEDIUM | MANAC INCORPORATED (JP) | 1993-03-31 | — | — | EP | disclosed |
| EP-0132983-B2 | PRODUCTION OF GELATIN SPHERICAL GELS AND THEIR USE | Hitachi Chemical Co., Ltd. (JP) | 1991-06-12 | — | — | EP | disclosed |
| EP-0374266-A1 | SOLID X-RAY CONTRAST MEDIUM | MANAC INCORPORATED (JP) | 1990-06-27 | — | — | EP | disclosed |
| EP-0374266-A1 | SOLID X-RAY CONTRAST MEDIUM | MANAC INCORPORATED (JP) | 1990-06-27 | — | — | EP | disclosed |
| WO-1990000408-A1 | SOLID X-RAY CONTRAST MEDIUM | MANAC INC. (JP) | 1990-01-25 | — | — | WO | disclosed |
| EP-0132983-B1 | Production of gelatin spherical gels and their use | Hitachi Chemical Co., Ltd. (JP) | 1987-10-07 | — | — | EP | disclosed |
| EP-0132983-A1 | Production of gelatin spherical gels and their use | Hitachi Chemical Co., Ltd. (JP) | 1985-02-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12582606-B2 | Tablet and method for producing tablet | GRHPR, RCC1, KIT | SMN1; SMN2 2523/4885LMNA 2295/4885KDM4E 1579/4885 |
| US-10716861-B2 | Composition intended to vectorise an anti-cancer agent | PHOSPHO1, POLQ, POLA1 | SMN1; SMN2 1615/4885LMNA 1893/4885KDM4E 4052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.